Creo Medical Limited (CREO.L)
GBp 16.25
(-5.8%)
GBp 16.25
(-5.8%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.7 Million GBP | 21.28% |
| 2022 | -27.61 Million GBP | -1.08% |
| 2021 | -27.54 Million GBP | -25.7% |
| 2020 | -21.76 Million GBP | -18.6% |
| 2019 | -17.95 Million GBP | -58.28% |
| 2018 | -11.37 Million GBP | -16.48% |
| 2017 | -9.96 Million GBP | -13.85% |
| 2016 | -8.76 Million GBP | -137.1% |
| 2015 | -3.69 Million GBP | -31.69% |
| 2014 | -2.8 Million GBP | -48.4% |
| 2013 | -1.88 Million GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -11.8 Million GBP | 0.0% |
| 2023 FY | - GBP | 21.28% |
| 2023 Q4 | -10.5 Million GBP | 0.0% |
| 2023 Q2 | -11.7 Million GBP | 0.0% |
| 2022 Q4 | -13.18 Million GBP | 0.0% |
| 2022 Q2 | -14.5 Million GBP | 0.0% |
| 2022 FY | - GBP | -1.08% |
| 2021 Q2 | -9.86 Million GBP | 0.0% |
| 2021 Q4 | -17.53 Million GBP | 0.0% |
| 2021 FY | - GBP | -25.7% |
| 2020 Q4 | -11.69 Million GBP | 0.0% |
| 2020 FY | - GBP | -18.6% |
| 2020 Q2 | -10.24 Million GBP | 0.0% |
| 2019 Q4 | -9.17 Million GBP | 0.0% |
| 2019 FY | - GBP | -58.28% |
| 2019 Q2 | -9.18 Million GBP | 0.0% |
| 2018 Q1 | -2.49 Million GBP | 0.0% |
| 2018 FY | - GBP | -16.48% |
| 2018 Q2 | -4.99 Million GBP | -100.61% |
| 2018 Q4 | -6.45 Million GBP | 0.0% |
| 2017 Q2 | -4.12 Million GBP | 0.0% |
| 2017 Q4 | -2.49 Million GBP | 0.0% |
| 2017 FY | - GBP | -13.85% |
| 2016 FY | - GBP | -137.1% |
| 2015 Q3 | -700.94 Thousand GBP | 0.0% |
| 2015 Q4 | -922.92 Thousand GBP | -31.67% |
| 2015 Q2 | -700.94 Thousand GBP | 0.0% |
| 2015 Q1 | -700.94 Thousand GBP | 0.0% |
| 2015 FY | - GBP | -31.69% |
| 2014 Q2 | -472.4 Thousand GBP | 0.0% |
| 2014 FY | - GBP | -48.4% |
| 2014 Q3 | -472.4 Thousand GBP | 0.0% |
| 2014 Q4 | -700.94 Thousand GBP | -48.38% |
| 2014 Q1 | -472.4 Thousand GBP | 0.0% |
| 2013 Q4 | -472.4 Thousand GBP | 0.0% |
| 2013 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|